Disrupting protein-protein interactions vital to cancer cells

Jalon Therapeutics aims to develop innovative therapies that inactivate yet untargeted vital tumor signaling pathways to transform the lives of people fighting cancer.

OVERCOMING THE LIMITATIONS OF CURRENT ANTICANCER THERAPIES

New strategies based on non-oncogene addiction for cancer patients

Jalon Therapeutics aims to leverage the potential of non-oncogene addiction to identify new therapeutic targets and develop disruptive anticancer treatment strategies.

Non-oncogene addiction

Non-oncogene addiction (NOA) offers potential novel, safer and more effective therapeutic strategies.

JRT39

Lead candidate JRT39 was selected based on optimized sequence, superior preclinical efficacy and preliminary stability & PK profiles.

Pipeline

Extensive portfolio of drug candidates. Pipeline with JRT39 already in in advanced preclinical stage and 6 other discovery-stage candidates.

FROM FUNDAMENTAL RESEARCH TO DRUG DEVELOPMENT

Researchers, physicians and executives dedicated to drug discovery and development

FROM FUNDAMENTAL RESEARCH TO DRUG DEVELOPMENT

The leadership team is composed of Jérôme Tiollier, co-founder and Chairman, David Loison, CEO, Hélène Sicard, COO and Jean-Luc Poyet, co-founder and CSO.

A Board of Directors with an extensive knowledge of biotech

The Board of Directors is composed of the leadership team members and other prominent experts in scientific discoveries, drug development and financing.

Scientific and Medical Advisory Board with renowned leaders in science and medicine.

The Scientific and Medical Advisory Board is composed of some co-founders of Jalon Therapeutics and other physicians and cancer specialists.

SCIENTIFIC, MEDICAL AND INDUSTRIAL COLLABORATIONS ARE KEY

Join our team

As Jalon Therapeutics further develops its scientific platform and its lead drug candidate JRT39 up to clinical stage, we seek bright and motivated professionals.

Investors & Partners

Jalon Therapeutics raised a pre-Seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. Its growth ambition is to raise a Seed immediately followed by a Series A to finance up to the clinical proof of concept of its lead candidate JRT39.

CONTACT US

Know more about us

Please feel free to contact us to know more about Jalon Therapeutics.

Disrupting protein-protein interactions vital to cancer cells

OVERCOMING THE LIMITATIONS OF CURRENT ANTICANCER THERAPIES

New strategies based on non-oncogene addiction for cancer patients

Non-oncogene addiction

JRT39

Pipeline

FROM FUNDAMENTAL RESEARCH TO DRUG DEVELOPMENT

Researchers, physicians and executives dedicated to drug discovery and development

FROM FUNDAMENTAL RESEARCH TO DRUG DEVELOPMENT

A Board of Directors with an extensive knowledge of biotech

Scientific and Medical Advisory Board with renowned leaders in science and medicine.

SCIENTIFIC, MEDICAL AND INDUSTRIAL COLLABORATIONS ARE KEY

Join our team

Investors & Partners

CONTACT US

Know more about us

Get in touch

Headquarters

Useful

E-MAIL ALERTS

Our London Shop